News articles about The Medicines (NASDAQ:MDCO) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Medicines earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2797009139292 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Medicines is Now Oversold (MDCO) (nasdaq.com)
- Elevian Launches to Develop Regenerative Medicines for Age-Related Diseases (prnewswire.com)
- $3.68 Million in Sales Expected for The Medicines Company (MDCO) This Quarter (americanbankingnews.com)
- The Medicines Company (MDCO) CEO Clive Meanwell Sells 50,000 Shares (americanbankingnews.com)
- The Medicines Company (MDCO) Expected to Announce Earnings of -$0.48 Per Share (americanbankingnews.com)
A number of brokerages have weighed in on MDCO. ValuEngine raised shares of The Medicines from a “hold” rating to a “buy” rating in a report on Friday, July 6th. BidaskClub raised shares of The Medicines from a “hold” rating to a “buy” rating in a research note on Tuesday, June 12th. Citigroup upped their price objective on shares of The Medicines from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, August 20th. Zacks Investment Research raised shares of The Medicines from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Tuesday, August 7th. Finally, B. Riley began coverage on shares of The Medicines in a research note on Thursday, June 7th. They set a “buy” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $52.63.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings results on Wednesday, August 1st. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.30. The Medicines had a negative return on equity of 394.33% and a negative net margin of 668.93%. The company had revenue of $1.67 million for the quarter, compared to the consensus estimate of $7.20 million. During the same quarter last year, the company posted ($0.72) earnings per share. The company’s revenue for the quarter was down 84.6% compared to the same quarter last year. sell-side analysts expect that The Medicines will post -2.51 EPS for the current fiscal year.
In other The Medicines news, CEO Clive Meanwell sold 50,000 shares of The Medicines stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $39.24, for a total transaction of $1,962,000.00. Following the completion of the transaction, the chief executive officer now directly owns 352,034 shares of the company’s stock, valued at $13,813,814.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders have sold 150,000 shares of company stock valued at $5,731,000. Company insiders own 10.29% of the company’s stock.
About The Medicines
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.